Kidney and Bladder Cancers :@0.646100:0.035749:0.919881:0.035749:0.919881:0.019993:0.646100:0.019993:0.011372:0.003848:0.013181:0.011738:0.012508:0.010314:0.005330:0.013143:0.011738:0.013181:0.005330:0.011045:0.003848:0.013143:0.013181:0.013181:0.012508:0.005792:0.005330:0.015644:0.013143:0.011738:0.012450:0.012508:0.005792:0.007466:0.005330
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
69:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
and  may  be  severe  or  life-threatening :@0.084848:0.096166:0.481092:0.096166:0.481092:0.080410:0.084848:0.080410:0.013143:0.011738:0.013181:0.005330:0.007551:0.018049:0.013143:0.010314:0.005330:0.007553:0.013123:0.012508:0.005330:0.007551:0.007466:0.012508:0.010660:0.012508:0.005717:0.012508:0.005330:0.007547:0.012604:0.005792:0.005330:0.007541:0.003848:0.003848:0.006042:0.012508:0.006388:0.006523:0.011738:0.005709:0.012508:0.013143:0.006523:0.012508:0.011738:0.003848:0.011738:0.012950:0.005330
and  therefore  premedication  is recom-:@0.084848:0.112557:0.475773:0.112557:0.475773:0.096801:0.084848:0.096801:0.013143:0.011738:0.013181:0.005330:0.006856:0.006523:0.011738:0.012508:0.005711:0.012508:0.006042:0.012604:0.005705:0.012508:0.005330:0.006854:0.013123:0.005715:0.012508:0.018049:0.012508:0.013181:0.003848:0.012450:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330:0.006852:0.003848:0.007466:0.012200:0.005713:0.012508:0.012450:0.012604:0.018049:0.006388
mended.:@0.084848:0.128947:0.171343:0.128947:0.171343:0.113192:0.084848:0.113192:0.018049:0.012508:0.011738:0.013181:0.012508:0.013181:0.005330
Angiogenesis target inhibition:  :@0.084848:0.162032:0.409361:0.162032:0.409361:0.144010:0.084848:0.144010:0.015822:0.012828:0.014111:0.005131:0.013683:0.014111:0.013683:0.012828:0.013683:0.009407:0.005131:0.009407:0.005987:0.006414:0.014111:0.006842:0.014111:0.013683:0.006414:0.005987:0.005131:0.012828:0.012828:0.005131:0.014111:0.005131:0.006414:0.005131:0.013683:0.012828:0.005987:0.005944:0.005987
mAb and VEGF TKIs:@0.084848:0.179891:0.285825:0.179891:0.285825:0.161870:0.084848:0.161870:0.020098:0.015822:0.014111:0.005987:0.014111:0.012828:0.014111:0.005987:0.014966:0.011118:0.017960:0.010263:0.005987:0.008980:0.013256:0.005987:0.009407
Bevacizumab is a mAb  that  binds circu-:@0.084848:0.197419:0.475769:0.197419:0.475769:0.181663:0.084848:0.181663:0.011045:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.008909:0.003848:0.007466:0.008909:0.013143:0.008909:0.018049:0.014239:0.013123:0.005330:0.003566:0.006523:0.011738:0.013143:0.006523:0.005330:0.003564:0.013123:0.003848:0.011738:0.013181:0.007466:0.008909:0.012450:0.003848:0.005659:0.012450:0.011699:0.006388
lating VEGF and prevents its interaction :@0.084848:0.213810:0.481071:0.213810:0.481071:0.198054:0.084848:0.198054:0.003848:0.013143:0.006523:0.003848:0.011738:0.012950:0.010410:0.013508:0.010314:0.016779:0.009333:0.010410:0.013143:0.011738:0.013181:0.010410:0.013123:0.005717:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.010410:0.003848:0.006523:0.007466:0.010410:0.003848:0.011738:0.006523:0.012508:0.005792:0.013143:0.012450:0.006523:0.003848:0.012604:0.011738:0.005330
with the VEGF receptor. Two phase III trials  :@0.084848:0.230201:0.481088:0.230201:0.481088:0.214445:0.084848:0.214445:0.015990:0.003848:0.006523:0.011738:0.005484:0.006523:0.011738:0.012508:0.005484:0.013508:0.010314:0.016779:0.009333:0.005484:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.004370:0.005330:0.005484:0.008324:0.015990:0.012604:0.005484:0.013123:0.011738:0.013143:0.007466:0.012508:0.005484:0.004349:0.004349:0.004349:0.005484:0.006523:0.005792:0.003848:0.013143:0.003848:0.007466:0.000000:0.005330
have demonstrated  improved  progres-:@0.084848:0.246592:0.475765:0.246592:0.475765:0.230836:0.084848:0.230836:0.011738:0.013143:0.010660:0.012508:0.014509:0.013181:0.012508:0.018049:0.012604:0.011738:0.007466:0.006523:0.005792:0.013143:0.006523:0.012508:0.013181:0.005330:0.009163:0.003848:0.018049:0.013123:0.005719:0.012604:0.010660:0.012508:0.013181:0.005330:0.009169:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.006388
sion-free survival (PFS) with bevacizumab :@0.084848:0.262983:0.481059:0.262983:0.481059:0.247227:0.084848:0.247227:0.007466:0.003848:0.012604:0.011738:0.006388:0.006042:0.005713:0.012508:0.012508:0.008101:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.008113:0.007100:0.011392:0.009333:0.009583:0.007100:0.008101:0.015990:0.003848:0.006523:0.011738:0.008101:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.005330
plus IFN compared to IFN alone.:@0.084848:0.279374:0.382542:0.279374:0.382542:0.263618:0.084848:0.263618:0.013123:0.003848:0.011699:0.007466:0.005330:0.004349:0.009333:0.014239:0.005330:0.012450:0.012604:0.018049:0.013123:0.013143:0.005709:0.012508:0.013181:0.005330:0.006523:0.012604:0.005330:0.004349:0.009333:0.014239:0.005330:0.013143:0.003848:0.012604:0.011738:0.012508:0.005330
6:@0.382514:0.273729:0.388729:0.273729:0.388729:0.264543:0.382514:0.264543:0.006215
The most important adverse events in :@0.103030:0.295733:0.481086:0.295733:0.481086:0.279977:0.103030:0.279977:0.008197:0.011738:0.012508:0.010410:0.018049:0.012604:0.007466:0.006523:0.010410:0.003848:0.018049:0.013123:0.012604:0.005792:0.006523:0.013143:0.011738:0.006523:0.010410:0.013143:0.013181:0.010660:0.012508:0.005792:0.007466:0.012508:0.010410:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.010410:0.003848:0.011738:0.005330
the bevacizumab arm included hyperten-:@0.084846:0.312124:0.475756:0.312124:0.475756:0.296368:0.084846:0.296368:0.006523:0.011738:0.012508:0.004897:0.013123:0.012508:0.010660:0.013143:0.012450:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.004907:0.013143:0.006325:0.018049:0.004907:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.012508:0.013181:0.004907:0.011738:0.010314:0.013123:0.012508:0.005792:0.006523:0.012508:0.011734:0.006388
sion, thrombo-embolic events, bleeding :@0.084846:0.328515:0.481078:0.328515:0.481078:0.312759:0.084846:0.312759:0.007466:0.003848:0.012604:0.011738:0.005330:0.012103:0.006523:0.011738:0.005707:0.012604:0.018049:0.013123:0.012604:0.006388:0.012508:0.018049:0.013123:0.012604:0.003848:0.003848:0.012450:0.012103:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.012103:0.013123:0.003848:0.012508:0.012508:0.013181:0.003848:0.011738:0.012950:0.005330
and gastro-intestinal perforation.:@0.084846:0.344906:0.389498:0.344906:0.389498:0.329150:0.084846:0.329150:0.013143:0.011738:0.013181:0.005330:0.012950:0.013143:0.007466:0.006523:0.005711:0.012604:0.006388:0.003848:0.011738:0.006523:0.012508:0.007466:0.006523:0.003848:0.011738:0.013143:0.003848:0.005330:0.013123:0.012508:0.006706:0.006042:0.012604:0.005792:0.013143:0.006523:0.003848:0.012604:0.011738:0.005330
Sunitinib is a multikinase inhibitor target-:@0.103030:0.361297:0.475769:0.361297:0.475769:0.345541:0.103030:0.345541:0.009583:0.011699:0.011738:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.006619:0.003848:0.007466:0.006619:0.013143:0.006619:0.018049:0.011699:0.003848:0.006523:0.003848:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.006619:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.006619:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.006388
ing VEGFR-1, VEGFR-2, PDGFR and c-Kit. It :@0.084846:0.377688:0.481067:0.377688:0.481067:0.361932:0.084846:0.361932:0.003848:0.011738:0.012950:0.006004:0.013508:0.010314:0.016779:0.009333:0.011680:0.006388:0.010660:0.005330:0.006004:0.013508:0.010314:0.016779:0.009333:0.011680:0.006388:0.010660:0.005330:0.006004:0.011392:0.014316:0.016779:0.009333:0.011680:0.006004:0.013143:0.011738:0.013181:0.006004:0.012450:0.006388:0.011372:0.003848:0.006523:0.005330:0.006004:0.004349:0.006523:0.005330
was more effective compared to IFN in a :@0.084846:0.394079:0.481113:0.394079:0.481113:0.378323:0.084846:0.378323:0.015990:0.013143:0.007466:0.006542:0.018049:0.012604:0.005713:0.012508:0.006542:0.012508:0.006096:0.006042:0.012508:0.012450:0.006523:0.003848:0.010660:0.012508:0.006542:0.012450:0.012604:0.018049:0.013123:0.013143:0.005713:0.012508:0.013181:0.006542:0.006523:0.012604:0.006531:0.004349:0.009333:0.014239:0.006531:0.003848:0.011738:0.006542:0.013143:0.005330
phase III trial of 750 patients, with good- or :@0.084846:0.410470:0.481111:0.410470:0.481111:0.394714:0.084846:0.394714:0.013123:0.011738:0.013143:0.007466:0.012508:0.005215:0.004349:0.004349:0.004349:0.005215:0.006523:0.005792:0.003848:0.013143:0.003848:0.005215:0.012604:0.006042:0.005215:0.010660:0.010660:0.010660:0.005215:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330:0.005215:0.015990:0.003848:0.006523:0.011738:0.005215:0.012950:0.012604:0.012604:0.013181:0.006388:0.005201:0.012604:0.005792:0.005330
intermediate-prognosis metastatic clear-:@0.084846:0.426861:0.475765:0.426861:0.475765:0.411105:0.084846:0.411105:0.003848:0.011738:0.006523:0.012508:0.006319:0.018049:0.012508:0.013181:0.003848:0.013143:0.006523:0.012508:0.006388:0.013123:0.005717:0.012604:0.012950:0.011738:0.012604:0.007466:0.003848:0.007466:0.011007:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.011007:0.012450:0.003848:0.012508:0.013143:0.005792:0.006388
cell RCC, in the first-line setting.:@0.084846:0.443252:0.373174:0.443252:0.373174:0.427496:0.084846:0.427496:0.012450:0.012508:0.003848:0.003848:0.005330:0.011680:0.015644:0.015644:0.005330:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.004686:0.004686:0.005792:0.007466:0.006523:0.006388:0.003848:0.003848:0.011738:0.012508:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
7:@0.373146:0.437585:0.379361:0.437585:0.379361:0.428399:0.373146:0.428399:0.006215
Sorafenib is a small molecule inhibitor of :@0.103030:0.459590:0.481078:0.459590:0.481078:0.443834:0.103030:0.443834:0.009583:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005715:0.003848:0.007466:0.005715:0.013143:0.005715:0.007466:0.018049:0.013143:0.003848:0.003848:0.005727:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.012508:0.005715:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.005715:0.012604:0.006042:0.005330
multiple  TKs, including VEGF receptor 2, :@0.084846:0.475981:0.481078:0.475981:0.481078:0.460225:0.084846:0.460225:0.018049:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.005330:0.005209:0.008197:0.011372:0.007466:0.005330:0.010526:0.003848:0.011738:0.012450:0.003848:0.011699:0.013181:0.003848:0.011738:0.012950:0.010526:0.013508:0.010314:0.016779:0.009333:0.010526:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.010526:0.010660:0.005330:0.005330
FLT3, PDGF receptor, and fibroblast growth :@0.084846:0.492372:0.481093:0.492372:0.481093:0.476616:0.084846:0.476616:0.009333:0.008003:0.008197:0.010660:0.005330:0.004911:0.011392:0.014316:0.016779:0.009333:0.004911:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.003760:0.005330:0.004911:0.013143:0.011738:0.013181:0.004915:0.004686:0.004686:0.013123:0.005711:0.012604:0.013123:0.003848:0.013143:0.007466:0.006523:0.004920:0.012950:0.005709:0.012604:0.015990:0.006523:0.011738:0.005330
factor  receptor-1  (FGFR1), as well as C-:@0.084846:0.508763:0.475748:0.508763:0.475748:0.493007:0.084846:0.493007:0.006042:0.013143:0.012450:0.006523:0.012604:0.005792:0.005330:0.004547:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.006388:0.010660:0.005330:0.004549:0.007100:0.009333:0.016779:0.009333:0.011680:0.010660:0.007100:0.005330:0.009891:0.013143:0.007466:0.009891:0.015990:0.012508:0.003848:0.003848:0.009891:0.013143:0.007466:0.009891:0.015644:0.006388
RAF and B-RAF. In the phase III TARGET tri-:@0.084846:0.525153:0.475765:0.525153:0.475765:0.509398:0.084846:0.509398:0.011680:0.014239:0.009333:0.006598:0.013143:0.011738:0.013181:0.006606:0.011045:0.006388:0.011680:0.014239:0.007807:0.005330:0.006604:0.004349:0.011738:0.006604:0.006523:0.011738:0.012508:0.006600:0.013123:0.011738:0.013143:0.007466:0.012508:0.006610:0.004349:0.004349:0.004349:0.006619:0.006633:0.014239:0.011680:0.016779:0.010314:0.008197:0.006600:0.006523:0.005792:0.003848:0.006388
al, patients with advanced RCC who had :@0.084846:0.541544:0.481101:0.541544:0.481101:0.525788:0.084846:0.525788:0.013143:0.003848:0.005330:0.005715:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005705:0.015990:0.003848:0.006523:0.011738:0.005715:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005715:0.011680:0.015644:0.015644:0.005715:0.015990:0.011738:0.012604:0.005702:0.011738:0.013143:0.013181:0.005330
failed  prior standard therapy were ran-:@0.084846:0.557935:0.475746:0.557935:0.475746:0.542179:0.084846:0.542179:0.006042:0.013143:0.003848:0.003848:0.012508:0.013181:0.005330:0.005921:0.013123:0.005792:0.003848:0.012604:0.005792:0.011238:0.007466:0.006523:0.013143:0.011738:0.013181:0.013143:0.005675:0.013181:0.011238:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.011238:0.015990:0.012508:0.005713:0.012508:0.011238:0.005792:0.013143:0.011738:0.006388
domly assigned to sorafenib or placebo. :@0.084846:0.574326:0.481086:0.574326:0.481086:0.558570:0.084846:0.558570:0.013181:0.012604:0.018049:0.003848:0.010314:0.008140:0.013143:0.007466:0.007466:0.003848:0.012950:0.011738:0.012508:0.013181:0.008140:0.006523:0.012604:0.008140:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.008140:0.012604:0.005792:0.008140:0.013123:0.003848:0.013143:0.012450:0.012508:0.013123:0.012604:0.005330:0.005330
The median PFS was significantly longer in :@0.084846:0.590717:0.481092:0.590717:0.481092:0.574961:0.084846:0.574961:0.008197:0.011738:0.012508:0.006131:0.018049:0.012508:0.013181:0.003848:0.013143:0.011738:0.006144:0.011392:0.009333:0.009583:0.006142:0.015990:0.013143:0.007466:0.006146:0.007466:0.003848:0.012950:0.011738:0.003848:0.004686:0.004686:0.012450:0.013143:0.011738:0.006523:0.003848:0.010314:0.006144:0.003848:0.012604:0.011738:0.012950:0.012508:0.005792:0.006129:0.003848:0.011738:0.005330
those receiving sorafenib compared with :@0.084846:0.607108:0.481086:0.607108:0.481086:0.591352:0.084846:0.591352:0.006523:0.011738:0.012604:0.007466:0.012508:0.007177:0.005713:0.012508:0.012450:0.012508:0.003848:0.010660:0.003848:0.011738:0.012950:0.007177:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.007177:0.012450:0.012604:0.018049:0.013123:0.013143:0.005717:0.012508:0.013181:0.007177:0.015990:0.003848:0.006523:0.011738:0.005330
placebo.:@0.084846:0.623499:0.170975:0.623499:0.170975:0.607743:0.084846:0.607743:0.013123:0.003848:0.013143:0.012450:0.012508:0.013123:0.012604:0.005330
8:@0.170979:0.617827:0.177194:0.617827:0.177194:0.608642:0.170979:0.608642:0.006215
Axitinib is an orally available inhibitor of :@0.103030:0.639832:0.481086:0.639832:0.481086:0.624076:0.103030:0.624076:0.014239:0.009236:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.006927:0.003848:0.007466:0.006927:0.013143:0.011738:0.006927:0.012604:0.005792:0.013143:0.003848:0.003848:0.010314:0.006943:0.013143:0.010660:0.013143:0.003848:0.003848:0.013143:0.013123:0.003848:0.012508:0.006950:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.006927:0.012604:0.006042:0.005330
the VEGF receptors 1, 2, and 3. Its registra-:@0.084846:0.656223:0.475733:0.656223:0.475733:0.640467:0.084846:0.640467:0.006523:0.011738:0.012508:0.005349:0.013508:0.010314:0.016779:0.009333:0.005349:0.005713:0.012508:0.012450:0.012508:0.013123:0.006523:0.012604:0.005792:0.007466:0.005349:0.010660:0.005330:0.005349:0.010660:0.005330:0.005349:0.013143:0.011738:0.013181:0.005349:0.010660:0.005330:0.005349:0.004349:0.006523:0.007466:0.005349:0.005713:0.012508:0.012950:0.003848:0.007466:0.006523:0.005792:0.013143:0.006388
tion was based on the AXIS phase III trial :@0.084846:0.672614:0.481047:0.672614:0.481047:0.656858:0.084846:0.656858:0.006523:0.003848:0.012604:0.011738:0.007620:0.015990:0.013143:0.007466:0.007620:0.013123:0.013143:0.007466:0.012508:0.013181:0.007620:0.012604:0.011738:0.007620:0.006523:0.011738:0.012508:0.007620:0.014239:0.011719:0.004349:0.009583:0.007620:0.013123:0.011738:0.013143:0.007466:0.012508:0.007620:0.004349:0.004349:0.004349:0.007620:0.006523:0.005792:0.003848:0.013143:0.003848:0.005330
in second-line metastatic clear-cell RCC :@0.084846:0.689005:0.481067:0.689005:0.481067:0.673249:0.084846:0.673249:0.003848:0.011738:0.009275:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.003848:0.003848:0.011738:0.012508:0.009275:0.018049:0.012508:0.006523:0.013143:0.007466:0.006523:0.013143:0.006523:0.003848:0.012450:0.009275:0.012450:0.003848:0.012508:0.013143:0.005792:0.006388:0.012450:0.012508:0.003848:0.003848:0.009275:0.011680:0.015644:0.015644:0.005330
patients who were randomly assigned to :@0.084846:0.705396:0.481074:0.705396:0.481074:0.689640:0.084846:0.689640:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.007774:0.015990:0.011738:0.012604:0.007774:0.015990:0.012508:0.005711:0.012508:0.007774:0.005792:0.013143:0.011738:0.013181:0.012604:0.018049:0.003848:0.010314:0.007774:0.013143:0.007466:0.007466:0.003848:0.012950:0.011738:0.012508:0.013181:0.007785:0.006523:0.012604:0.005330
treatment with either axitinib or sorafenib.:@0.084846:0.721787:0.469550:0.721787:0.469550:0.706031:0.084846:0.706031:0.006523:0.005709:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005026:0.015990:0.003848:0.006523:0.011738:0.005042:0.012508:0.003848:0.006523:0.011738:0.012508:0.005792:0.005026:0.013143:0.009236:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.005042:0.012604:0.005792:0.005030:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005330
9:@0.469540:0.716141:0.475755:0.716141:0.475755:0.706956:0.469540:0.706956:0.006215
Pazopanib  is an oral agent multikinase :@0.103030:0.738146:0.481086:0.738146:0.481086:0.722390:0.103030:0.722390:0.011392:0.013143:0.008178:0.012604:0.013123:0.013143:0.011738:0.003848:0.013123:0.005330:0.003002:0.003848:0.007466:0.008332:0.013143:0.011738:0.008332:0.012604:0.005792:0.013143:0.003848:0.008332:0.013143:0.012950:0.012508:0.011738:0.006523:0.008332:0.018049:0.011699:0.003848:0.006523:0.003848:0.009660:0.003848:0.011738:0.013143:0.007466:0.012508:0.005330
inhibitor that was approved for patients :@0.084846:0.754537:0.481072:0.754537:0.481072:0.738781:0.084846:0.738781:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.009987:0.006523:0.011738:0.013143:0.006523:0.009987:0.015990:0.013143:0.007466:0.009987:0.013143:0.013123:0.013123:0.005721:0.012604:0.010660:0.012508:0.013181:0.009987:0.006042:0.012604:0.005792:0.009987:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
with previously untreated advanced renal :@0.084846:0.770928:0.481086:0.770928:0.481086:0.755172:0.084846:0.755172:0.015990:0.003848:0.006523:0.011738:0.005138:0.013123:0.005715:0.012508:0.010660:0.003848:0.012604:0.011699:0.007466:0.003848:0.010314:0.005138:0.011699:0.011738:0.006523:0.005707:0.012508:0.013143:0.006523:0.012508:0.013181:0.005128:0.013143:0.013181:0.010660:0.013143:0.011738:0.012450:0.012508:0.013181:0.005138:0.005713:0.012508:0.011738:0.013143:0.003848:0.005330
cell carcinoma and for patients who had :@0.084846:0.787319:0.481088:0.787319:0.481088:0.771563:0.084846:0.771563:0.012450:0.012508:0.003848:0.003848:0.006581:0.012450:0.013143:0.005657:0.012450:0.003848:0.011738:0.012604:0.018049:0.013143:0.006567:0.013143:0.011738:0.013181:0.006569:0.006042:0.012604:0.005792:0.006560:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.006569:0.015990:0.011738:0.012604:0.006564:0.011738:0.013143:0.013181:0.005330
progressed on cytokine therapy.:@0.084846:0.803710:0.386519:0.803710:0.386519:0.787954:0.084846:0.787954:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.012508:0.013181:0.005330:0.012604:0.011738:0.005330:0.012450:0.010314:0.006523:0.012604:0.009660:0.003848:0.011738:0.012508:0.005330:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330
10:@0.386498:0.798070:0.398928:0.798070:0.398928:0.788884:0.386498:0.788884:0.006215:0.006215
Checkpoint inhibitors:@0.084848:0.836783:0.303784:0.836783:0.303784:0.818762:0.084848:0.818762:0.016677:0.012828:0.013683:0.013683:0.012401:0.014111:0.013683:0.005131:0.012828:0.006414:0.005987:0.005131:0.012828:0.012828:0.005131:0.014111:0.005131:0.006414:0.013683:0.006842:0.009407
Immunotherapy  with  mAbs directed :@0.084848:0.854315:0.481099:0.854315:0.481099:0.838559:0.084848:0.838559:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.018126:0.015990:0.003848:0.006523:0.011738:0.005330:0.018136:0.018049:0.014239:0.013123:0.007466:0.023476:0.013181:0.003848:0.005717:0.012508:0.012450:0.006523:0.012508:0.013181:0.005330
against PD-1 or cytotoxic T-lymphocyte :@0.084848:0.870706:0.481088:0.870706:0.481088:0.854950:0.084848:0.854950:0.013143:0.012950:0.013143:0.003848:0.011738:0.007466:0.006523:0.012084:0.011392:0.014316:0.006388:0.010660:0.012084:0.012604:0.005792:0.012084:0.012450:0.010314:0.006523:0.012604:0.006523:0.012604:0.009236:0.003848:0.012450:0.012084:0.008197:0.006388:0.003848:0.010314:0.018049:0.013123:0.011738:0.012604:0.012450:0.010314:0.006523:0.012508:0.005330
antigen  (CTLA-4)  has  become  an  impor-:@0.084848:0.887097:0.475758:0.887097:0.475758:0.871341:0.084848:0.871341:0.013143:0.011738:0.006523:0.003848:0.012950:0.012508:0.011738:0.005330:0.003060:0.007100:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.007100:0.005330:0.003063:0.011738:0.013143:0.007466:0.005330:0.003069:0.013123:0.012508:0.012450:0.012604:0.018049:0.012508:0.005330:0.003060:0.013143:0.011738:0.005330:0.003065:0.003848:0.018049:0.013123:0.012604:0.005792:0.006388
tant part of the treatment of mRCC.:@0.084848:0.903488:0.420938:0.903488:0.420938:0.887732:0.084848:0.887732:0.006523:0.013143:0.011738:0.006523:0.005330:0.013123:0.013143:0.005792:0.006523:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.006523:0.005678:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.005330:0.012604:0.006042:0.005330:0.018049:0.011680:0.015644:0.015644:0.005330
Nivolumab (PD-1 inhibitor) has been ap-:@0.103032:0.919879:0.475769:0.919879:0.475769:0.904123:0.103032:0.904123:0.014239:0.003848:0.010660:0.012604:0.003848:0.011699:0.018049:0.013143:0.013123:0.005330:0.007100:0.011392:0.014316:0.006388:0.010660:0.005330:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007100:0.005319:0.011738:0.013143:0.007466:0.005330:0.013123:0.012508:0.012508:0.011738:0.005315:0.013143:0.013123:0.006388
proved as a second-line therapy following :@0.084848:0.936270:0.481105:0.936270:0.481105:0.920514:0.084848:0.920514:0.013123:0.005715:0.012604:0.010660:0.012508:0.013181:0.004895:0.013143:0.007466:0.004907:0.013143:0.004907:0.007466:0.012508:0.012450:0.012604:0.011738:0.013181:0.006388:0.003848:0.003848:0.011738:0.012508:0.004893:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.004891:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330
TKI  therapy  based on  a  phase III trial  :@0.524249:0.096192:0.920481:0.096166:0.920481:0.080410:0.524249:0.080436:0.008197:0.011372:0.004349:0.005330:0.006138:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.006142:0.013123:0.013143:0.007466:0.012508:0.013181:0.011488:0.012604:0.011738:0.005330:0.006140:0.013143:0.005330:0.006146:0.013123:0.011738:0.013143:0.007466:0.012508:0.011488:0.004349:0.004349:0.004349:0.011488:0.006523:0.005792:0.003848:0.013143:0.003848:0.012410:0.422434
11:@0.902716:0.090547:0.915146:0.090547:0.915146:0.081361:0.902716:0.081361:0.006215:0.006215
where overall survival  and response rate :@0.524241:0.112557:0.920488:0.112557:0.920488:0.096801:0.524241:0.096801:0.015990:0.011738:0.012508:0.005709:0.012508:0.008755:0.012604:0.010660:0.012508:0.005792:0.013143:0.003848:0.003848:0.008755:0.007466:0.011699:0.005792:0.010660:0.003848:0.010660:0.013143:0.003848:0.005330:0.003441:0.013143:0.011738:0.013181:0.008755:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.008755:0.005792:0.013143:0.006523:0.012508:0.005330
was better  than everolimus. (Median OS :@0.524241:0.128947:0.920467:0.128947:0.920467:0.113192:0.524241:0.113192:0.015990:0.013143:0.007466:0.008890:0.013123:0.012508:0.006523:0.006523:0.012508:0.005792:0.005330:0.003548:0.006523:0.011738:0.013143:0.011738:0.008890:0.012508:0.010660:0.012508:0.005713:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.005330:0.008890:0.007100:0.017684:0.012508:0.013181:0.003848:0.013143:0.011738:0.008890:0.016722:0.009583:0.005330
25 :@0.524241:0.145338:0.550892:0.145338:0.550892:0.129582:0.524241:0.129582:0.010660:0.010660:0.005330
versus:@0.550738:0.145338:0.606329:0.145338:0.606329:0.129582:0.550738:0.129582:0.010660:0.012508:0.005792:0.007466:0.011699:0.007466
 19.6m, HR 0.73, 95% CI 0.57-0.93.) :@0.606329:0.145338:0.920435:0.145338:0.920435:0.129582:0.606329:0.129582:0.005157:0.010660:0.010660:0.005330:0.010660:0.018049:0.005330:0.005157:0.013143:0.011680:0.005157:0.010660:0.005330:0.010660:0.010660:0.005330:0.005169:0.010660:0.010660:0.014913:0.005157:0.015644:0.004349:0.005157:0.010660:0.005330:0.010660:0.010660:0.006388:0.010660:0.005330:0.010660:0.010660:0.005330:0.007100:0.005330
The toxicity profile was also more favour-:@0.524241:0.161729:0.915166:0.161729:0.915166:0.145973:0.524241:0.145973:0.008197:0.011738:0.012508:0.007841:0.006523:0.012604:0.009236:0.003848:0.012450:0.003848:0.006523:0.010314:0.007859:0.013123:0.005715:0.012604:0.004686:0.004686:0.003848:0.012508:0.007847:0.015990:0.013143:0.007466:0.007857:0.013143:0.003848:0.007466:0.012604:0.007857:0.018049:0.012604:0.005707:0.012508:0.007849:0.006042:0.013143:0.010660:0.012604:0.011699:0.005792:0.006388
able. The combination of nivolumab and :@0.524241:0.178120:0.920473:0.178120:0.920473:0.162364:0.524241:0.162364:0.013143:0.013123:0.003848:0.012508:0.005330:0.007081:0.008197:0.011738:0.012508:0.007081:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007081:0.012604:0.006042:0.007081:0.011738:0.003848:0.010660:0.012604:0.003848:0.011699:0.018049:0.013143:0.013123:0.007093:0.013143:0.011738:0.013181:0.005330
ipilumimab (CTLA-4 inhibitor) has been ap-:@0.524241:0.194511:0.915135:0.194511:0.915135:0.178755:0.524241:0.178755:0.003848:0.013123:0.003848:0.003848:0.011699:0.018049:0.003848:0.018049:0.013143:0.013123:0.004449:0.007100:0.015644:0.008197:0.008890:0.014239:0.006388:0.010660:0.004426:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007100:0.004426:0.011738:0.013143:0.007466:0.004426:0.013123:0.012508:0.012508:0.011738:0.004426:0.013143:0.013123:0.006388
proved in treatment-naïve patients.:@0.524241:0.210902:0.855316:0.210902:0.855316:0.195146:0.524241:0.195146:0.013123:0.005715:0.012604:0.010660:0.012508:0.013181:0.005330:0.003848:0.011738:0.005330:0.006523:0.005705:0.012508:0.013143:0.006523:0.018049:0.012508:0.011738:0.006523:0.006388:0.011738:0.013143:0.003848:0.010660:0.012508:0.005330:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
12:@0.855309:0.205246:0.867739:0.205246:0.867739:0.196061:0.855309:0.196061:0.006215:0.006215
Other mAbs (atezoluzimab and pem-:@0.542424:0.227251:0.915149:0.227251:0.915149:0.211495:0.542424:0.211495:0.016722:0.006523:0.011738:0.012508:0.005792:0.011622:0.018049:0.014239:0.013123:0.007466:0.011622:0.007100:0.013143:0.006523:0.012508:0.008178:0.012604:0.003848:0.011699:0.008178:0.003848:0.018049:0.013143:0.013123:0.011622:0.013143:0.011738:0.013181:0.011622:0.013123:0.012508:0.018049:0.006388
brolizumab) are also being trialled  in this :@0.524240:0.243642:0.920458:0.243642:0.920458:0.227886:0.524240:0.227886:0.013123:0.005715:0.012604:0.003848:0.003848:0.008178:0.011699:0.018049:0.013143:0.013123:0.007100:0.008332:0.013143:0.005715:0.012508:0.008332:0.013143:0.003848:0.007466:0.012604:0.008332:0.013123:0.012508:0.003848:0.011738:0.012950:0.008332:0.006523:0.005792:0.003848:0.013143:0.003848:0.003848:0.012508:0.013181:0.005330:0.003019:0.003848:0.011738:0.008332:0.006523:0.011738:0.003848:0.007466:0.005330
setting, but results are not yet published. :@0.524240:0.260033:0.920458:0.260033:0.920458:0.244277:0.524240:0.244277:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330:0.008332:0.013123:0.011699:0.006523:0.008332:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.008332:0.013143:0.005715:0.012508:0.008332:0.011738:0.012604:0.006523:0.008332:0.010314:0.012508:0.006523:0.008332:0.013123:0.011699:0.013123:0.003848:0.003848:0.007466:0.011738:0.012508:0.013181:0.005330:0.005330
Various combinations of  PD-1 inhibitors :@0.524240:0.276424:0.920491:0.276424:0.920491:0.260668:0.524240:0.260668:0.011509:0.013143:0.005792:0.003848:0.012604:0.011699:0.007466:0.013951:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.013951:0.012604:0.006042:0.005330:0.008611:0.011392:0.014316:0.006388:0.010660:0.013951:0.003848:0.011738:0.011738:0.003848:0.013123:0.003848:0.006523:0.012604:0.005792:0.007466:0.005330
with TKIs are being investigated and seem :@0.524240:0.292815:0.920518:0.292815:0.920518:0.277059:0.524240:0.277059:0.015990:0.003848:0.006523:0.011738:0.005407:0.008197:0.011372:0.004349:0.007466:0.005407:0.013143:0.005715:0.012508:0.005407:0.013123:0.012508:0.003848:0.011738:0.012950:0.005407:0.003848:0.011738:0.010660:0.012508:0.007466:0.006523:0.003848:0.012950:0.013143:0.006523:0.012508:0.013181:0.005407:0.013143:0.011738:0.013181:0.005407:0.007466:0.012508:0.012508:0.018049:0.005330
promising.:@0.524240:0.309206:0.618912:0.309206:0.618912:0.293450:0.524240:0.293450:0.013123:0.005715:0.012604:0.018049:0.003848:0.007466:0.003848:0.011738:0.012950:0.005330
Patterns  of  response  differ  from  those :@0.542424:0.325597:0.920487:0.325597:0.920487:0.309841:0.542424:0.309841:0.011392:0.013143:0.006523:0.006523:0.012508:0.006183:0.011738:0.007466:0.005330:0.005628:0.012604:0.006042:0.005330:0.005623:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.005330:0.005625:0.013181:0.003848:0.006104:0.006042:0.012508:0.005792:0.005330:0.005619:0.006042:0.005713:0.012604:0.018049:0.005330:0.005623:0.006523:0.011738:0.012604:0.007466:0.012508:0.005330
with molecular targeted agents or cyto-:@0.524240:0.341987:0.915163:0.341987:0.915163:0.326232:0.524240:0.326232:0.015990:0.003848:0.006523:0.011738:0.008948:0.018049:0.012604:0.003848:0.012508:0.012450:0.011699:0.003848:0.013143:0.005792:0.008948:0.006523:0.013143:0.005805:0.012950:0.012508:0.006523:0.012508:0.013181:0.008948:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.008948:0.012604:0.005792:0.008948:0.012450:0.010314:0.006523:0.012604:0.006388
toxic chemotherapy. Special immune-:@0.524240:0.358378:0.915134:0.358378:0.915134:0.342622:0.524240:0.342622:0.006523:0.012604:0.009236:0.003848:0.012450:0.016548:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011722:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.016548:0.009583:0.013123:0.012508:0.012450:0.003848:0.013143:0.003848:0.016548:0.003848:0.018049:0.018049:0.011699:0.011738:0.012508:0.006388
response criteria were developed for pa-:@0.524240:0.374769:0.915159:0.374769:0.915159:0.359013:0.524240:0.359013:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.007197:0.012450:0.005792:0.003848:0.006523:0.012508:0.005792:0.003848:0.013143:0.007187:0.015990:0.012508:0.005711:0.012508:0.007197:0.013181:0.012508:0.010660:0.012508:0.003848:0.012604:0.013123:0.012508:0.013181:0.007197:0.006042:0.012604:0.005792:0.007183:0.013123:0.013143:0.006388
tients in the setting of melanoma and now :@0.524240:0.391160:0.920500:0.391160:0.920500:0.375404:0.524240:0.375404:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.004897:0.003848:0.011738:0.004907:0.006523:0.011738:0.012508:0.004891:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.004897:0.012604:0.006042:0.004895:0.018049:0.012508:0.003848:0.013143:0.011738:0.012604:0.018049:0.013143:0.004897:0.013143:0.011738:0.013181:0.004907:0.011738:0.012604:0.015990:0.005330
apply here as well. Lesions may undergo :@0.524240:0.407551:0.920493:0.407551:0.920493:0.391795:0.524240:0.391795:0.013143:0.013123:0.013123:0.003848:0.010314:0.007716:0.011738:0.012508:0.005711:0.012508:0.007705:0.013143:0.007466:0.007716:0.015990:0.012508:0.003848:0.003848:0.005330:0.007716:0.008890:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.007707:0.018049:0.013143:0.010314:0.007716:0.011699:0.011738:0.013181:0.012508:0.005792:0.012950:0.012604:0.005330
progression before they respond, take :@0.524240:0.423942:0.920477:0.423942:0.920477:0.408186:0.524240:0.408186:0.013123:0.005715:0.012604:0.012950:0.005705:0.012508:0.007466:0.007466:0.003848:0.012604:0.011738:0.014528:0.013123:0.012508:0.006042:0.012604:0.005707:0.012508:0.014528:0.006523:0.011738:0.012508:0.010314:0.014528:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.005330:0.014528:0.006523:0.013143:0.009660:0.012508:0.005330
long to respond or shrink and become :@0.524240:0.440333:0.920495:0.440333:0.920495:0.424577:0.524240:0.424577:0.003848:0.012604:0.011738:0.012950:0.011064:0.006523:0.012604:0.011064:0.005711:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.011064:0.012604:0.005792:0.011064:0.007466:0.011738:0.005792:0.003848:0.011738:0.009660:0.011064:0.013143:0.011738:0.013181:0.011064:0.013123:0.012508:0.012450:0.012604:0.018049:0.012508:0.005330
long-term responders.:@0.524240:0.456724:0.727917:0.456724:0.727917:0.440968:0.524240:0.440968:0.003848:0.012604:0.011738:0.012950:0.006388:0.006523:0.012508:0.006313:0.018049:0.005330:0.005709:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.012508:0.005792:0.007466:0.005330
Toxicity of these mAbs is completely differ-:@0.542424:0.473115:0.915184:0.473115:0.915184:0.457359:0.542424:0.457359:0.006868:0.012219:0.008852:0.003464:0.012065:0.003464:0.006138:0.009929:0.004618:0.012219:0.005657:0.004618:0.006138:0.011353:0.012123:0.007081:0.012123:0.004618:0.017665:0.013855:0.012738:0.007081:0.004618:0.003464:0.007081:0.004618:0.012065:0.012219:0.017665:0.012738:0.003464:0.012123:0.006138:0.012123:0.003464:0.009929:0.004618:0.012796:0.003464:0.005713:0.005657:0.012123:0.005407:0.006388
ent to that of chemotherapy and typically :@0.524240:0.489506:0.920483:0.489506:0.920483:0.473750:0.524240:0.473750:0.012123:0.011353:0.006138:0.006927:0.006138:0.012219:0.006927:0.006138:0.011353:0.012758:0.006138:0.006927:0.012219:0.005657:0.006927:0.012065:0.011353:0.012123:0.017665:0.012219:0.006138:0.011353:0.012123:0.005407:0.012758:0.012738:0.009929:0.006927:0.012758:0.011353:0.012796:0.006927:0.006138:0.009929:0.012738:0.003464:0.012065:0.012758:0.003464:0.003464:0.010318:0.005330
presents with skin, gastro-intestinal and later :@0.524240:0.505897:0.920477:0.505897:0.920477:0.490141:0.524240:0.490141:0.012738:0.005328:0.012123:0.007081:0.012123:0.011353:0.006138:0.007081:0.005532:0.015606:0.003464:0.006138:0.011353:0.005530:0.007081:0.009275:0.003464:0.011353:0.004945:0.005530:0.012565:0.012758:0.007081:0.006138:0.005328:0.012219:0.006004:0.003464:0.011353:0.006138:0.012123:0.007081:0.006138:0.003464:0.011353:0.012758:0.003464:0.005532:0.012758:0.011353:0.012796:0.005532:0.003464:0.012758:0.006138:0.012123:0.005788:0.005330
endocrine abnormalities. The full clinical pic-:@0.524240:0.522288:0.915138:0.522288:0.915138:0.506532:0.524240:0.506532:0.012123:0.011353:0.012796:0.012219:0.012065:0.005407:0.003464:0.011353:0.012123:0.003989:0.012758:0.012738:0.011353:0.012219:0.005938:0.017665:0.012758:0.003464:0.003464:0.006138:0.003464:0.012123:0.007081:0.004945:0.003989:0.007812:0.011353:0.012123:0.003991:0.005657:0.011315:0.003464:0.003464:0.003991:0.012065:0.003464:0.003464:0.011353:0.003464:0.012065:0.012758:0.003464:0.003991:0.012738:0.003464:0.012065:0.006388
ture is still unfolding as follow-up after treat-:@0.524240:0.538679:0.915145:0.538679:0.915145:0.522923:0.524240:0.522923:0.006138:0.011315:0.005328:0.012123:0.006312:0.003464:0.007081:0.006312:0.007081:0.006138:0.003464:0.003464:0.003464:0.006312:0.011315:0.011353:0.005657:0.012219:0.003464:0.012796:0.003464:0.011353:0.012565:0.006312:0.012758:0.007081:0.006312:0.005657:0.012219:0.003464:0.003464:0.012219:0.015606:0.006004:0.011315:0.012738:0.006312:0.012758:0.005657:0.006138:0.012123:0.005407:0.006312:0.006138:0.005328:0.012123:0.012758:0.006138:0.006388
ment reflects the long-term side effects.:@0.524240:0.555070:0.878827:0.555070:0.878827:0.539314:0.524240:0.539314:0.017665:0.012123:0.011353:0.006138:0.004945:0.005328:0.012123:0.004474:0.004474:0.012123:0.012065:0.006138:0.007081:0.004945:0.006138:0.011353:0.012123:0.004945:0.003464:0.012219:0.011353:0.012565:0.006004:0.006138:0.012123:0.005938:0.017665:0.004945:0.007081:0.003464:0.012796:0.012123:0.004945:0.012123:0.005713:0.005657:0.012123:0.012065:0.006138:0.007081:0.005330
Price will limit access as all of these drugs :@0.542424:0.571461:0.920479:0.571461:0.920479:0.555705:0.542424:0.555705:0.011392:0.005792:0.003848:0.012450:0.012508:0.004451:0.015990:0.003848:0.003848:0.003848:0.004464:0.003848:0.003848:0.018049:0.003848:0.006523:0.004464:0.013143:0.012450:0.012450:0.012508:0.007466:0.007466:0.004464:0.013143:0.007466:0.004464:0.013143:0.003848:0.003848:0.004464:0.012604:0.006042:0.004451:0.006523:0.011738:0.012508:0.007466:0.012508:0.004453:0.013181:0.005792:0.011699:0.012950:0.007466:0.005330
are very expensive.:@0.524240:0.587852:0.704464:0.587852:0.704464:0.572096:0.524240:0.572096:0.013143:0.005715:0.012508:0.005330:0.010660:0.012508:0.005792:0.010314:0.005330:0.012508:0.009236:0.013123:0.012508:0.011738:0.007466:0.003848:0.010660:0.012508:0.005330
NON-CLEAR-CELL RCC:@0.524242:0.620830:0.755578:0.620830:0.755578:0.603015:0.524242:0.603015:0.015822:0.017960:0.015822:0.008980:0.016677:0.009407:0.011118:0.015822:0.012401:0.008980:0.016677:0.011118:0.009407:0.009407:0.005987:0.012401:0.016677:0.016677
The  activity of  agents  such  as sunitinib, :@0.524242:0.638362:0.920483:0.638362:0.920483:0.622606:0.524242:0.622606:0.008197:0.011738:0.012508:0.005330:0.005503:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.010853:0.012604:0.006042:0.005330:0.005513:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.005507:0.007466:0.011699:0.012450:0.011738:0.005330:0.005511:0.013143:0.007466:0.010853:0.007466:0.011699:0.011738:0.003848:0.006523:0.003848:0.011738:0.003848:0.013123:0.005330:0.005330
sorafenib and temsirolimus in patients with :@0.524242:0.654753:0.920489:0.654753:0.920489:0.638997:0.524242:0.638997:0.007466:0.012604:0.005792:0.013143:0.006042:0.012508:0.011738:0.003848:0.013123:0.005276:0.013143:0.011738:0.013181:0.005280:0.006523:0.012508:0.018049:0.007466:0.003848:0.005719:0.012604:0.003848:0.003848:0.018049:0.011699:0.007466:0.005292:0.003848:0.011738:0.005278:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005278:0.015990:0.003848:0.006523:0.011738:0.005330
non-clear-cell RCC still  has to be con-:@0.524242:0.671144:0.915147:0.671144:0.915147:0.655388:0.524242:0.655388:0.011738:0.012604:0.011738:0.006388:0.012450:0.003848:0.012508:0.013143:0.005792:0.006388:0.012450:0.012508:0.003848:0.003848:0.012142:0.011680:0.015644:0.015644:0.012142:0.007466:0.006523:0.003848:0.003848:0.003848:0.005330:0.006827:0.011738:0.013143:0.007466:0.012142:0.006523:0.012604:0.012142:0.013123:0.012508:0.012142:0.012450:0.012604:0.011738:0.006388
firmed,  although  preliminary  results  and :@0.524242:0.687535:0.920481:0.687535:0.920481:0.671779:0.524242:0.671779:0.004686:0.004686:0.006319:0.018049:0.012508:0.013181:0.005330:0.005330:0.006340:0.013143:0.003848:0.006523:0.011738:0.012604:0.011699:0.012950:0.011738:0.005330:0.006342:0.013123:0.005715:0.012508:0.003848:0.003848:0.018049:0.003848:0.011738:0.013143:0.005792:0.010314:0.005330:0.006344:0.005713:0.012508:0.007466:0.011699:0.003848:0.006523:0.007466:0.005330:0.006348:0.013143:0.011738:0.013181:0.005330
subset analyses suggest that these agents :@0.524242:0.703926:0.920491:0.703926:0.920491:0.688170:0.524242:0.688170:0.007466:0.011699:0.013123:0.007466:0.012508:0.006523:0.005600:0.013143:0.011738:0.013143:0.003848:0.010314:0.007466:0.012508:0.007478:0.005588:0.007466:0.011699:0.012950:0.012950:0.012508:0.007466:0.006523:0.005584:0.006523:0.011738:0.013143:0.006523:0.005582:0.006523:0.011738:0.012508:0.007466:0.012508:0.005584:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330
have some activity. Subsets of non-clear-:@0.524242:0.720317:0.915151:0.720317:0.915151:0.704561:0.524242:0.704561:0.011738:0.013143:0.010660:0.012508:0.007197:0.007466:0.012604:0.018049:0.012508:0.007197:0.013143:0.012450:0.006523:0.003848:0.010660:0.003848:0.006523:0.010314:0.005330:0.007197:0.009583:0.011699:0.013123:0.007466:0.012508:0.006523:0.007466:0.007197:0.012604:0.006042:0.007197:0.011738:0.012604:0.011738:0.006388:0.012450:0.003848:0.012508:0.013143:0.005792:0.006388
cell tumours  occasionally  also respond :@0.524242:0.736708:0.920483:0.736708:0.920483:0.720952:0.524242:0.720952:0.012450:0.012508:0.003848:0.003848:0.013393:0.006523:0.011699:0.018049:0.012604:0.011699:0.005792:0.007466:0.005330:0.008053:0.012604:0.012450:0.012450:0.013143:0.007466:0.003848:0.012604:0.011738:0.013143:0.003848:0.003848:0.010314:0.005330:0.008076:0.013143:0.003848:0.007466:0.012604:0.013393:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.013181:0.005330
to  chemotherapy. Major  responses  have :@0.524242:0.753099:0.920485:0.753099:0.920485:0.737343:0.524242:0.737343:0.006523:0.012604:0.005330:0.003217:0.012450:0.011738:0.012508:0.018049:0.012604:0.006523:0.011738:0.012508:0.005792:0.013129:0.013123:0.010314:0.005330:0.008563:0.017684:0.013143:0.003906:0.012604:0.005792:0.005330:0.003219:0.005713:0.012508:0.007466:0.013123:0.012604:0.011738:0.007466:0.012508:0.007466:0.005330:0.003223:0.011738:0.013143:0.010660:0.012508:0.005330
been reported with various combinations :@0.524242:0.769490:0.920470:0.769490:0.920470:0.753734:0.524242:0.753734:0.013123:0.012508:0.012508:0.011738:0.007158:0.005713:0.012508:0.013123:0.012604:0.005792:0.006523:0.012508:0.013171:0.007158:0.015990:0.003848:0.006523:0.011738:0.007158:0.010660:0.013143:0.005792:0.003848:0.012604:0.011699:0.007466:0.007158:0.012450:0.012604:0.018049:0.013123:0.003848:0.011738:0.013143:0.006523:0.003848:0.012604:0.011738:0.007466:0.005330
of platinum agents, taxanes, gemcitabine :@0.524242:0.785881:0.920481:0.785881:0.920481:0.770125:0.524242:0.770125:0.012604:0.006042:0.005215:0.013123:0.003848:0.013143:0.006523:0.003848:0.011738:0.011699:0.018049:0.005215:0.013143:0.012950:0.012508:0.011738:0.006523:0.007466:0.005330:0.005215:0.006523:0.013143:0.009236:0.013143:0.011738:0.012508:0.007466:0.005330:0.005215:0.012950:0.012508:0.018049:0.012450:0.003848:0.006523:0.013143:0.013123:0.003848:0.011738:0.012508:0.005330
and doxorubicin  in patients with collect-:@0.524242:0.802271:0.915190:0.802271:0.915190:0.786516:0.524242:0.786516:0.013143:0.011738:0.013181:0.008717:0.013181:0.012604:0.009236:0.012604:0.005792:0.011699:0.013123:0.003848:0.012450:0.003848:0.011738:0.005330:0.003387:0.003848:0.011738:0.008717:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.008717:0.015990:0.003848:0.006523:0.011738:0.008717:0.012450:0.012604:0.003848:0.003848:0.012508:0.012450:0.006523:0.006388
ing-duct  tumour  and  sarcomatoid  RCCs. :@0.524242:0.818662:0.920487:0.818662:0.920487:0.802906:0.524242:0.802906:0.003848:0.011738:0.012950:0.006388:0.013181:0.011699:0.012450:0.006523:0.005330:0.002986:0.006523:0.011699:0.018049:0.012604:0.011690:0.005792:0.005330:0.002988:0.013143:0.011738:0.013181:0.005330:0.002992:0.007466:0.013143:0.005663:0.012450:0.012604:0.018049:0.013143:0.006523:0.012604:0.003848:0.013181:0.005330:0.002992:0.011680:0.015644:0.015644:0.007466:0.005330:0.005330
Immunotherapy  is being investigated in :@0.524242:0.835053:0.920483:0.835053:0.920483:0.819297:0.524242:0.819297:0.004349:0.018049:0.018049:0.011699:0.011738:0.012604:0.006523:0.011738:0.012508:0.005792:0.013143:0.013123:0.010314:0.005330:0.005986:0.003848:0.007466:0.011334:0.013123:0.012508:0.003848:0.011738:0.012950:0.011334:0.003848:0.011738:0.010660:0.012508:0.007466:0.006523:0.003848:0.012950:0.013143:0.006523:0.012508:0.013181:0.011334:0.003848:0.011738:0.005330
this setting.:@0.524242:0.851444:0.626034:0.851444:0.626034:0.835688:0.524242:0.835688:0.006523:0.011738:0.003848:0.007466:0.005330:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330
BLADDER CANCER:@0.524242:0.884794:0.728382:0.884794:0.728382:0.865197:0.524242:0.865197:0.013641:0.010348:0.017404:0.016463:0.016463:0.012230:0.013641:0.006585:0.018344:0.017404:0.017404:0.018344:0.012230:0.013641
Bladder cancer is the most common can-:@0.524242:0.903472:0.915170:0.903472:0.915170:0.887716:0.524242:0.887716:0.011045:0.003848:0.013143:0.013181:0.013181:0.012508:0.005792:0.005715:0.012450:0.013143:0.011738:0.012450:0.012508:0.005792:0.005694:0.003848:0.007466:0.005715:0.006523:0.011738:0.012508:0.005694:0.018049:0.012604:0.007466:0.006523:0.005700:0.012450:0.012604:0.018049:0.018049:0.012604:0.011738:0.005696:0.012450:0.013143:0.011738:0.006388
cer of the urinary tract with a peak inci-:@0.524242:0.919863:0.915151:0.919863:0.915151:0.904107:0.524242:0.904107:0.012450:0.012508:0.005792:0.008255:0.012604:0.006042:0.008255:0.006523:0.011738:0.012508:0.008255:0.011699:0.005792:0.003848:0.011738:0.013143:0.005792:0.010314:0.008255:0.006523:0.005792:0.013143:0.012450:0.006523:0.008255:0.015990:0.003848:0.006523:0.011738:0.008255:0.013143:0.008255:0.013123:0.012508:0.013143:0.009660:0.008255:0.003848:0.011738:0.012450:0.003848:0.006388
dence in the sixth to eighth decade. An :@0.524242:0.936254:0.920499:0.936254:0.920499:0.920498:0.524242:0.920498:0.013181:0.012508:0.011738:0.012450:0.012508:0.008091:0.003848:0.011738:0.008101:0.006523:0.011738:0.012508:0.008091:0.007466:0.003848:0.009236:0.006523:0.011738:0.008101:0.006523:0.012604:0.008091:0.012508:0.003848:0.012950:0.011738:0.006523:0.011738:0.008090:0.013181:0.012508:0.012450:0.013143:0.013181:0.012508:0.005330:0.008101:0.014239:0.011738:0.005330